Megumi Inaba

Minami, 8620965, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Radiotherapy-Induced Pleural Mesothelioma in a Childhood Leukaemia Survivor: A Case Report.

Radiotherapy-Induced Pleural Mesothelioma in a Childhood Leukaemia Survivor: A Case Report.

Journal: Respirology case reports

Published: July 09, 2025

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 06, 2025

Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.

Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 30, 2025

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 21, 2025

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).

Journal: Clinical lung cancer

Published: January 01, 2025

Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.

Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.

Journal: Clinical lung cancer

Published: February 18, 2024

Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].

Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 30, 2023

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 09, 2023

Pulmonary Nocardiosis With Endobronchial Involvement Caused by Nocardiaaraoensis.

Pulmonary Nocardiosis With Endobronchial Involvement Caused by Nocardiaaraoensis.

Journal: Chest

Published: March 17, 2023

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.

Journal: Therapeutic advances in medical oncology

Published: August 10, 2022

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 01, 2022

Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).

Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).

Journal: Therapeutic advances in medical oncology

Published: April 07, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026